Immunomedics Expands Partnership With Roche on Lung Cancer Treatments
July 13 2020 - 5:22PM
Dow Jones News
By Kimberly Chin
Immunomedics Inc. said it has extended its partnership with
Roche Holding Ltd. on clinical trials of their combined treatments
for patients with metastatic urothelial cancer and metastatic
non-small cell lung cancer.
The two companies will look at the efficacy of Immunomedics'
Trodelvy treatment in combination with Roche's Tecentriq.
Roche will conduct two open-label, randomized Phase 1b/2 studies
that will examine patients who have failed platinum-containing
chemotherapy and have begun using Tecentriq and Trodelvy together,
as well as patients who use Tecentriq alone. A second study will
look at patients who take the combined treatments and docetaxel
alone.
Separately, Immunomedics said it will launch a Phase 2 study of
Trodelvy for its first patient who has localized triple-negative
breast cancer. The treatment will be administered before
tumor-removal surgery, the company said. The primary aim of the
study will be to show a pathological complete response rate to the
treatment, Immunomedics said.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
July 13, 2020 17:07 ET (21:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024